PARAMUS, N.J., Nov. 6 /PRNewswire/ -- Mayne Pharma (USA) Inc. has announced that it is launching Epirubicin Hydrochloride for Injection (lyophilized) 50mg/vial (30mL). Mayne Pharma intends to follow-up in the near future with the addition of Epirubicin Hydrochloride for Injection (lyophilized) packaged in a 200mg/vial (100mL vial). Mayne Pharma (USA) Inc.'s new drug application for Epirubicin was approved by the U.S. Food and Drug Administration on September 15, 2006.
Epirubicin Hydrochloride for Injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
James Hageman, Senior V.P. and Head of U.S. Commercial Operations said “The addition of Epirubicin Hydrochloride for Injection to our product line is a very exciting event because it further enhances our oncology product range which already includes products such as Paclitaxel, Carboplatin, Methotrexate and Mitroxantrone.”
Mayne Pharma (USA) is a specialty pharmaceutical company focused on developing, manufacturing and selling a comprehensive range of products to oncology customers in more than 65 countries around the world. The company seeks to augment its growth by accessing additional marketed or development- stage products either through acquisition or partnership. Mayne Pharma generated sales of more than $US800 million in its financial year ended June 30, 2006 and is listed on the Australian Stock Exchange under the symbol ‘MYP’. For more information about Mayne Pharma, please visit www.maynepharma.com.
Mayne Pharma (USA) Inc.
CONTACT: Andrew Rowe, Vice President Investor Relations, Mayne PharmaLimited, +44-20-7420-8426, +44-7920-598-353 (mobile),andrew.rowe@maynepharma.com
Web site: http://www.maynepharma.com/
